If you have been reading about anti-doping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-04. Numbers and descriptions here follow the published literature rather than marketing material.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
=== Pharmacodynamics === DPIA is a norepinephrine transporter inhibitor with an IC₅₀ value of 3.1 µM, as well as a dopamine transporter inhibitor with a potency approximately 13 times weaker than that of amphetamine, but 7 times more potent than amphetamine in inhibiting the serotonin transporter, although, unlike amphetamine, DPIA does not exhibit monoamine-releasing activity. It exhibits moderate affinity for 5-HT1A serotonin receptors (Ki = 3.5 µM) and for alpha-1A-adrenoreceptors (Ki = 0.12 µM), and binds to alpha-2A-adrenoreceptors and TAAR1. In experiments on rodents, DPIA produced the same central effects and toxicity as amphetamine, but was less potent. Interestingly, unlike amphetamine, DPIA caused a reduction in heart rate and blood pressure (exhibiting cardiodepressant properties).
==== 2009–2015 ==== The JWP published its report on elements 113–116 and 118 in 2011. It recognised the JINR–LLNL collaboration as having discovered elements 114 and 116, but did not accept either team's claim to element 113 and did not accept the JINR–LLNL claims to elements 115 and 118. The JINR–LLNL claim to elements 115 and 113 had been founded on chemical identification of their daughter dubnium, but the JWP objected that current theory could not distinguish between superheavy group 4 and group 5 elements by their chemical properties with enough confidence to allow this assignment. The decay properties of all the nuclei in the decay chain of element 115 had not been previously characterised before the JINR experiments, a situation which the JWP generally considers "troublesome, but not necessarily exclusive", and with the small number of atoms produced with neither known daughters nor cross-reactions the JWP considered that their criteria had not been fulfilled. The JWP did not accept the Riken team's claim either due to inconsistencies in the decay data, the small number of atoms of element 113 produced, and the lack of unambiguous anchors to known isotopes. In early 2009, the Riken team synthesised the decay product 266Bh directly in the 248Cm + 23Na reaction to establish its link with 278113 as a cross-bombardment. They also established the branched decay of 262Db, which sometimes underwent spontaneous fission and sometimes underwent the previously known alpha decay to 258Lr.
Myomeres are overlapping "cones" of muscle fibers bound by connective tissue. The shape of myomeres varies by species. Myomeres are commonly zig-zaged, being stacks or lines of muscle fibers shaped like "V" (lancelets), "W" (fishes), or straight (tetrapods). Generally, cyclostome myomeres are arranged in vertical strips while those of jawed fishes are folded in a complex manner due to their derived nature and evolution of advanced swimming capability. Specifically, myomeres of elasmobranchs and eels are W-shaped, while the myomeres of tetrapods, such as mudpuppies, run vertically and do not display complex folding. Myomeres overlap each other in succession, meaning myomere activation also allows neighboring myomeres to activate. They are innervated by spinal nerves, which pass into each myomere. Myomeres are made up of myoglobin-rich dark muscle as well as white muscle. Dark muscles generally function as slow-twitch muscle fibers while white muscle is composed of fast-twitch fibers. In gnathostomes, the myomeres are separated by myoseptal tendons. Specifically, these are the myorhabdoid tendons, the lateral tendons, the epineural tendon, and the epipleural tendon.
=== Plants === In plants the glyoxylate cycle occurs in special peroxisomes which are called glyoxysomes. This cycle allows seeds to use lipids as a source of energy to form the shoot during germination. The seed cannot produce biomass using photosynthesis because of lack of an organ to perform this function. The lipid stores of germinating seeds are used for the formation of the carbohydrates that fuel the growth and development of the organism. The glyoxylate cycle can also provide plants with another aspect of metabolic diversity. This cycle allows plants to take in acetate both as a carbon source and as a source of energy. Acetate is converted to acetyl CoA (similar to the TCA cycle). This acetyl CoA can proceed through the glyoxylate cycle, and some succinate is released during the cycle. The four carbon succinate molecule can be transformed into a variety of carbohydrates through combinations of other metabolic processes; the plant can synthesize molecules using acetate as a source for carbon. The acetyl CoA can also react with glyoxylate to produce some NADPH from NADP+, which is used to drive energy synthesis in the form of ATP later in the electron transport chain.
The First Strike Ration (FSR) is a compact assault United States military ration. It is designed to be consumed on the move during the first 72 hours of conflict. It was created by the United States Army Soldier Systems Center in Natick, Massachusetts. The U.S. Army said the FSR substantially reduces weight and load and is intended to enhance a consumer's physical performance, mental acuity, and mobility. In July 2025, it was replaced by the Close Combat Assault Ration.
Sources: en.wikipedia.org
== History == The World Health Organization defines Health as a state of complete physical, mental and social well-being. This is a utopian and unattainable ideal as Moving the goalposts when an achievement is made. Possibly the first use of the term 'positive health' was in 1924 when it was considered a double positive as health itself is a positive term. In the year 2000, it was described as the ability to cope with biological, Psychological, and social stress, and parameters such as pain-bearing capacity and Vital capacity were suggested as its indicators. In 2008, positive health was explained as a combination of excellent status on biological, subjective, and functional measures, including factors such as optimism, stable marriage, and lower blood pressure level. In 2011, it was defined as one's ability to adapt and self-manage in the face of social, physical, and emotional challenges, and it constituted psycho-social parameters. In 2023, positive health was defined as the ability to live long in good health.[1] An effort has been made to identify major indicators that can objectively measure a person's positive health in this sense.
=== Non-encoded nucleotides are added to the ends of RNA molecules === Molecular analysis of mRNA molecules showed that, following transcription, mRNAs have non-DNA-encoded nucleotides added to both their 5′ and 3′ ends (guanosine caps and poly-A, respectively). Enzymes were also identified that add and maintain the universal CCA sequence on the 3′ end of tRNA molecules. These events are among the first discovered examples of RNA processing, a complex series of reactions that are needed to convert RNA primary transcripts into biologically active RNA molecules.
Tongue-clicking and grunting are the most common sounds and are made in cordial situations to conspecifics, offspring and occasionally humans. When at ease, they produce a loud rumbling hum. During times of fear or nervousness, bears may moan, huff or blow air. Warning sounds include jaw-clicking and lip-popping. In aggressive interactions, black bears produce guttural pulsing calls that may sound like growling. Cubs squeal, bawl or scream when anxious and make a motor-like humming sound when comfortable or nursing. American black bears often mark trees using their teeth and claws as a form of communication with other bears, a behavior common to many species of bears.
=== Post-translational modifications === Human protein C has at least five types of post-translational modifications: (1) gamma-carboxylation on the first nine glutamic acid residues in the protein sequence. This modification event is performed by a vitamin K-dependent microsomal carboxylase. The full complement of Gla is required to give full activity to protein C. (2) beta-Hydroxylation of Asp71 in one of the two EGF-like domains to give erythro-L-beta-hydroxy-aspartate (bHA). The modification is required for functional activity as was demonstrated by mutating Asp71 to Glu. (3) N-linked glycosylation at three possible glycosylation sites. Plasma human Protein C has been reported to be 23% carbohydrate by weight. (4) Disulfide formation. (5) Multiple proteolytic cleavages of the polypeptide backbone to remove an 18 amino acid signal peptide, a 24 amino acid propeptide and then cleavages at amino acids 155-156 and 157-158 to yield the two-chain structure of the circulating zymogen.
Sources: en.wikipedia.org
Evidence for a "virus first" or "virus world" hypothesis, which may support theories of the RNA world, was suggested in 2015. One of the difficulties for the study of the origins of viruses is their high rate of mutation; this is particularly the case in RNA retroviruses like HIV. A 2015 study compared protein fold structures across different branches of the tree of life, where researchers can reconstruct the evolutionary histories of the folds and of the organisms whose genomes code for those folds. They argue that protein folds are better markers of ancient events as their three-dimensional structures can be maintained even as the sequences that code for those begin to change. Thus, the viral protein repertoire retain traces of ancient evolutionary history that can be recovered using advanced bioinformatics approaches. Those researchers think that "the prolonged pressure of genome and particle size reduction eventually reduced virocells into modern viruses (identified by the complete loss of cellular makeup), meanwhile other coexisting cellular lineages diversified into modern cells." The data suggest that viruses originated from ancient cells that co-existed with the ancestors of modern cells. These ancient cells likely contained segmented RNA genomes. A computational model (2015) has shown that virus capsids may have originated in the RNA world and served as a means of horizontal transfer between replicator communities.
==== Multilateral Initiatives ==== As the U.S. expanded its development-assistance efforts in the course of the 1950s, other industrial countries were recovering economically from World War II and were increasingly able to engage in development assistance. The U.S. supported their involvement through several multilateral initiatives. Three of these initiatives expanded World Bank facilities.
== Interactions == Miconazole is partly absorbed in the intestinal tract when used orally, as with the oral gel, and possibly when used vaginally. This can lead to increased concentrations of drugs that are metabolized by the liver enzymes CYP3A4 and CYP2C9, because miconazole inhibits these enzymes. Such interactions occur for example with anticoagulants of the warfarin type, phenytoin, some newer atypical antipsychotics, ciclosporin, and most statins used to treat hypercholesterolemia. These interactions are not relevant for miconazole that is applied to the skin.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.